3,4-Diaminopyridine

Jump to navigation Jump to search
3,4-Diaminopyridine
File:Diaminopyridine.png
Clinical data
Routes of
administration		Oral
Legal status
Legal status
  • Phase III
Pharmacokinetic data
Bioavailability30% [1],[2]
Identifiers
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC5H7N3
Molar mass109.13

3,4-Diaminopyridine is an experimental drug used in the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca2+ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate.

It has also been proposed for use in multiple sclerosis.[3]

See also

References

  1. ↑ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve. 24: 1236–1238.
  2. ↑ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome". Acta Neurol Scand. 88: 136–140.
  3. ↑ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. PMID 16472864.


Template:Pharma-stub

Retrieved from "https://www.wikidoc.org/index.php?title=3,4-Diaminopyridine&oldid=602958"